×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:MEDP

Medpace (MEDP) Stock Forecast, Price & News

$147.37
+11.83 (+8.73%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$137.55
$147.87
50-Day Range
$130.20
$168.03
52-Week Range
$126.94
$231.00
Volume
403,512 shs
Average Volume
344,418 shs
Market Capitalization
$4.96 billion
P/E Ratio
27.49
Dividend Yield
N/A
Beta
1.53
30 days | 90 days | 365 days | Advanced Chart
Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Medpace logo

About Medpace

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
4,500
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$6.20 per share
Book Value
$17.98 per share

Profitability

Net Income
$181.85 million
Pretax Margin
18.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
26,716,000
Market Cap
$4.96 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/25/2022
Today
5/28/2022
Next Earnings (Estimated)
7/25/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

161st out of 1,424 stocks

Commercial Physical Research Industry

3rd out of 23 stocks

Analyst Opinion: 2.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -













Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace
or view top-rated stocks.

Are investors shorting Medpace?

Medpace saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,650,000 shares, an increase of 24.1% from the April 30th total of 1,330,000 shares. Based on an average daily volume of 313,600 shares, the short-interest ratio is currently 5.3 days. Currently, 6.0% of the shares of the stock are short sold.
View Medpace's Short Interest
.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 25th 2022.
View our earnings forecast for Medpace
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, April, 25th. The company reported $1.69 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.43. The business earned $330.90 million during the quarter, compared to analysts' expectations of $327.09 million. Medpace had a trailing twelve-month return on equity of 24.17% and a net margin of 16.47%. The company's quarterly revenue was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.17 EPS.
View Medpace's earnings history
.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY22 earnings guidance on Monday, April, 25th. The company provided earnings per share guidance of $5.72-6.06 for the period, compared to the consensus earnings per share estimate of $5.85. The company issued revenue guidance of $1.40-1.46 billion, compared to the consensus revenue estimate of $1.41 billion.

What price target have analysts set for MEDP?

3 analysts have issued 1 year price targets for Medpace's shares. Their forecasts range from $167.90 to $205.00. On average, they expect Medpace's stock price to reach $182.63 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price.
View analysts' price targets for Medpace
or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?
Medpace's management team includes the following people:
What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.27%), Vanguard Group Inc. (9.30%), Wasatch Advisors Inc. (8.11%), State Street Corp (2.67%), Invesco Ltd. (2.66%) and Echo Street Capital Management LLC (2.07%). Company insiders that own Medpace stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends for Medpace
.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Polen Capital Management LLC, Invesco Ltd., First Trust Advisors LP, Meritage Portfolio Management, Vanguard Group Inc., Russell Investments Group Ltd., and Assenagon Asset Management S.A.. Company insiders that have sold Medpace company stock in the last year include Ashley M Keating, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Stephen P Ewald, Susan E Burwig, and Tom C King.
View insider buying and selling activity for Medpace
or view top insider-selling stocks.

Which institutional investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Boston Trust Walden Corp, Echo Street Capital Management LLC, Grandeur Peak Global Advisors LLC, BlackRock Inc., Riverbridge Partners LLC, Woodline Partners LP, and Raymond James & Associates. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace
or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $147.37.

How much money does Medpace make?

Medpace has a market capitalization of $4.96 billion and generates $1.14 billion in revenue each year. The company earns $181.85 million in net income (profit) each year or $5.36 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 4,500 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911, via email at [email protected], or via fax at 513-579-0444.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.